Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dexmedetomidine and recovery outcomes after rhinoplasty
IRCT20200825048515N57Phase 3Completed
- Sponsor
- Isfahan University of Medical Sciences
- Start
- Aug 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of dexmedetomidine, sponsored by Isfahan University of Medical Sciences. Primary endpoint: Recovery indicators after rhinoplasty. Started Aug 2022; status: completed.
02
Drugs
dexmedetomidine
Beyond the preview
Go deeper on IRCT20200825048515N57.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20200825048515N57.